Fortress Biotech, Inc. (FBIOP) Cash from Financing Activities (2010 - 2025)

Fortress Biotech's Cash from Financing Activities history runs 16 years deep, the most recent figure standing at $5.7 million for Q4 2025.

• In Q4 2025, Cash from Financing Activities fell 77.88% year-over-year to $5.7 million; the TTM figure through Dec 2025 stood at $77.4 million (up 9.63% YoY), while the FY2025 annual figure was $77.4 million, up 9.63% from the prior year.
• Cash from Financing Activities for Q4 2025 stood at $5.7 million, down from $15.1 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $78.7 million in Q1 2021, with the low at -$30.4 million in Q2 2023.
• The 5-year median for Cash from Financing Activities is $16.8 million (2022), against an average of $20.3 million.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities tumbled 1115.75% in 2023, then jumped 455.96% in 2025.
• Fortress Biotech's Cash from Financing Activities stood at $38.9 million in 2021, then plunged by 52.19% to $18.6 million in 2022, then surged by 134.28% to $43.6 million in 2023, then slumped by 40.84% to $25.8 million in 2024, then slumped by 77.88% to $5.7 million in 2025.
• Business Quant data shows FBIOP's Cash from Financing Activities at $5.7 million in Q4 2025, $15.1 million in Q3 2025, and $4.5 million in Q2 2025.